CatalYm doses first patient in Phase II/III VINCIT trial

​CatalYm has commenced dosing the first subject in its Phase II/III VINCIT trial, assessing the safety and efficacy of its lead anti-GDF-15 antibody, visugromab, in cancer-associated cachexia.

The post CatalYm doses first patient in Phase II/III VINCIT trial appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

Jade reports interim Phase I results of JADE101 for IgAN
MicroPort launches LBBOT Solution commercially in Europe and Australia
Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn
SKIA secures FDA 510(k) clearance for AR surgical platform
FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us